Clinical trials: Heparin-Induced Thrombocytopenia
Heparin-Induced Thrombocytopenia
The HIT-TRAP Trial
Randomised, double blind trial in non-intensive care trauma patients comparing unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) in heparin-induced thrombocytopenia (HIT).
- Trial name
- NCT00196417
- Testing
- Standard heparin (UFH) versus certoparin (LMWH)
- Where
- Germany
- Volunteers
- 600 people
- Sponsor
- University Medicine Greifswald
Heparin-induced Thrombocytopenia, HIT
Characterization and Quantification of Platelet/Leukocyte Aggregates in Patients With Suspected Heparin-induced Thrombocytopenia
The investigators would like to analyze platelet/leukoplak activation, quantify and morphologically characterize these aggregates using in vitro analysis, directly on whole blood from adult patients with suspected HIT.
- Conditions
- Heparin-induced Thrombocytopenia, HIT, Platelet Activation, Platelets
- Trial name
- HITSTREAM (NCT06033300)
- Testing
- blood sample
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Thrombocytopenia, Immune, Heparin Induced Thrombocytopenia
A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia
The purpose of this study is to evaluate the efficacy and safety of VLX-1005, a 12-lipoxygenase (12-LOX) enzyme inhibitor in treating heparin induced thrombocytopenia (HIT).
- Trial name
- NCT05785819
- Testing
- VLX-1005
- Where
- 14 sites in United States
- Volunteers
- 24 people
- Sponsor
- Veralox Therapeutics
Aneurysmal Subarachnoid Hemorrhage, Neurobehavioral Manifestations
Aneurysmal Subarachnoid Hemorrhage Trial RandOmizing Heparin
A Blind-adjudication Multi-center Phase II Randomized Clinical Trial of Continuous Low-dose Intravenous Heparin Therapy in Coiled Low-grade Aneurysmal Subarachnoid Hemorrhage Patients with Significant Hemorrhage Burden.
- Conditions
- Aneurysmal Subarachnoid Hemorrhage, Neurobehavioral Manifestations, Vasospasm, Intracranial, Intracranial Aneurysm
- Trial name
- ASTROH (NCT02501434)
- Testing
- Continuous Low-Dose IV Unfractionated Heparin Infusion
- Where
- 9 sites in United States
- Volunteers
- 88 people
- Sponsor
- Robert F. James
Heparin-induced Thrombocytopenia
A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects
The study is designed to characterize the safety and tolerability of VLX-1005 and argatroban administered intravenously, either alone or in combination; and the pharmacokinetics and pharmacodynamics and potential interaction of…
- Trial name
- NCT05325346
- Testing
- VLX-1005, Argatroban
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Veralox Therapeutics
Heparin-Induced Thrombocytopenia
Efficacy and Safety Study of Argatroban to Treat Heparin-Induced Thrombocytopenia
The purpose of the study is to evaluate efficacy and safety of argatroban in the patients with heparin-induced thrombocytopenia (HIT)/ HIT and thrombosis syndrome (HITTS).
- Trial name
- NCT00198588
- Testing
- argatroban
- Where
- 20 sites in Japan
- Volunteers
- 8 people
- Sponsor
- Ministry of Health, Labour and Welfare, Japan
Heparin-induced Thrombocytopenia
Argatroban Monitoring in Acute Suspected Heparin-induced Thrombocytopenia.
Heparin-induced thrombocytopenia (HIT) is a rare but potentially serious complication of heparin therapy. , argatroban is the alternative anticoagulant of choice in patients with suspected HIT and renal impairment, high bleeding…
- Trial name
- TIH-FM (NCT06066762)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Heparin-induced Thrombocytopenia
Pharmacogenomics of Heparin-Induced Thrombocytopenia
The purpose of this research is to identify genomic markers that can predict heparin-induced thrombocytopenia (HIT), which is a very serious side effect to heparin.
- Trial name
- PHIT (NCT02717039)
- Testing
- Blood Draw
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- University of Arizona
Dialysis; Complications, Heparin-induced Thrombocytopenia
Multicenter Study on Dialysis Modalities for End-stage Chronic Renal Failure Patients With Heparin-induced Thrombocytopenia
This research is based on the hypothesis that the Hydrolink®-NV dialysis membrane could allow the realization of quality dialysis with a significant reduction in the doses of Orgaran®, or even a total cessation of the…
- Conditions
- Dialysis; Complications, Heparin-induced Thrombocytopenia, Chronic Renal Failure
- Trial name
- MODIATIH (NCT05586854)
- Testing
- Hydrolink NV membrane
- Where
- France
- Volunteers
- 20 people
- Sponsor
- GCS Ramsay Santé pour l'Enseignement et la Recherche
Heparin-induced Thrombocytopenia (HIT)
Optimizing the Diagnosis of Heparin Induced Thrombocytopenia
Multicentre (Ottawa and Halifax) prospective cohort study using a diagnostic approach in patients clinically suspected to have HIT that combines pretest probability assessment with quantitative interpretation of anti-PF4 assay.
- Trial name
- HIT (NCT03148912)
- Testing
- Diagnostic algorithm
- Where
- Canada
- Volunteers
- 107 people
- Sponsor
- Ottawa Hospital Research Institute
Heparin-Induced Thrombocytopenia
Validating 4Ts for Heparin Induced Thrombocytopenia (HIT)
The purpose of this study is to evaluate a scoring tool to help determine the presence of Heparin Induced Thrombocytopenia (HIT), which is an adverse reaction to heparin.
- Trial name
- NCT00946400
- Testing
- Scoring 4Ts and Chong scale, Blood draw
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Medstar Health Research Institute
Heparin-Induced Thrombocytopenia, Heparin-induced Thrombocytopenia and Thrombosis Syndrome
Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients
To monitor the frequency of the development of thrombocytopenia in patients with Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome receiving bivalirudin during Percutaneous Coronary…
- Trial name
- NCT00759083
- Testing
- bivalirudin
- Where
- United States
- Sponsor
- The Medicines Company
Heparin-induced Thrombocytopenia
Heparin-Induced Thrombocytopenia: Development and Validation of a Predictive Clinical
Although Heparin-induced thrombocytopenia (HIT) is a rare complication of heparin treatment, it results in a high rate of morbidity and mortality, the cumulative rate of thrombosis recurrence, amputation and death approaching 52…
- Trial name
- Score-TIH (NCT00748839)
- Where
- 27 sites in France
- Volunteers
- 2,700 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Heparin-Induced Thrombocytopenia
A Study on the Prevalence of Heparin-Induced Thrombocytopenia in Cardiovascular Patients
Several clinical studies in Western countries have revealed that the prevalence of HIT is 0.5 to 5%, varying depending on the clinical setting.
- Trial name
- NCT00198575
- Where
- 13 sites in Japan
- Volunteers
- 1,500 people
- Sponsor
- Ministry of Health, Labour and Welfare, Japan
Heparin-induced Thrombocytopenia (HIT)
Rapid Diagnosis of Heparin-Induced Thrombocytopenia in Surgical Critically Ill Patients
The early diagnosis of heparin-induced thrombocytopenia is particularly difficult in surgical critically ill patients. If the use of rapid immunological diagnostic methods and pretest scoring systems has been proposed in the…
- Trial name
- TIH (NCT02790567)
- Testing
- HEP score, 4Ts score, ID-PaGIA test
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Heparin-induced Thrombocytopenia, Heparin-induced Thrombocytopenia and Thrombosis
Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT)
This research study is studying a drug as a possible treatment for heparin induced thrombocytopenia (HIT) or Heparin-induced Thrombocytopenia and Thrombosis (HITT). The drug involved in this study is apixaban.
- Trial name
- NCT03594045
- Testing
- Apixaban
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Massachusetts General Hospital
Heparin Induced Thrombocytopenia
Heparin-Induced Thrombocytopenia - Retrospective Analysis of Data on Incidence and Outcomes Study
HIT-RADIO is a study of patients who had a positive heparin PF-4 antibody test between 1/21/2008 and 9/25/2008 at selected hospitals.
- Trial name
- HIT-RADIO (NCT01178333)
- Where
- 21 sites in United States
- Volunteers
- 668 people
- Sponsor
- Carelon Research
Deep Venous Thrombosis
Study Comparing Desirudin With Heparin to Prevent Vein Clots After Heart and Lung Surgery
A blood clot in the veins, also known as deep venous thrombosis (DVT), is one of the most common complications after surgery. This may result in death if a clot breaks off and travel to the lungs; this is referred to as pulmonary…
- Trial name
- NCT00329433
- Testing
- Desirudin (Iprivask™), Heparin
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Washington University School of Medicine
Heparin-induced Thrombocytopenia Type II
Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II
The purpose of this study is to collect data on the clinical management of Argatroban in patients with suspected or confirmed heparin-induced thrombocytopenia Type II, with or without ongoing thrombosis who require parenteral…
- Trial name
- NCT00861692
- Testing
- argatroban
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Tanabe Pharma Corporation
Heparin Induced Thrombocytopenia (HIT)
Argatroban Versus Lepirudin in Critically Ill Patients
The purpose of this study is to test the hypotheses that argatroban significantly increases efficacy and safety of renal replacement therapy measured as life time of haemodialysis filters as compared to lepirudin
- Trial name
- ALiCia (NCT00798525)
- Testing
- Argatroban, Lepirudin
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- Heinrich-Heine University, Duesseldorf